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Abstract To evaluate mechanisms that mediate passage of
unconjugated bilirubin (UCB) across placenta, the transport of
[3H]UCB was studied in the human trophoblastic, BeWo cell line.
When plotted against the unbound UCB concentration [Bf],
uptake exhibited saturative kinetics with a similar apparent Km
(V30 nM) for BeWo cells grown either in polarized (Transwell)
or non-polarized fashion (dish). UCB release from cells, but not
uptake, was inhibited by sulfobromophthalein but not by
taurocholate, and almost abolished by MK571, a specific
inhibitor of the activity of multidrug resistance-associated
proteins (MRPs). MRP1 and MRP5 were both present in BeWo
cells and the expression of MRP1, but not MRP5, was markedly
higher in polarized cells. These data indicate that UCB is taken
up from the fetal circulation by a still undefined, saturative
process not shared by other organic anions and is then excreted
to maternal circulation by proteins of the MRP family. ß 2001
Federation of European Biochemical Societies. Published by
Elsevier Science B.V. All rights reserved.
Key words: Placenta; Expression; Fetus;
Multidrug resistance-associated protein; Bilirubin;
Transport
1. Introduction
Although bilirubin transport and metabolism have been
largely studied in adults, little information is available on
these processes during fetal life. Fetal production of uncon-
jugated bilirubin (UCB) is higher than in adult life, and there
is a physiological, sudden increase in hemoglobin catabolism
perinatally [1]. Theoretically, the fetus is at risk for accumu-
lation of UCB, due to the almost complete absence in the fetal
liver of the only enzyme that conjugates UCB, uridine-diphos-
phate glucoronosyltransferase-1A1 [2]. The fetus is also more
susceptible to neurotoxicity from retained UCB, because K-
fetoprotein has a lower ability to bind UCB than does adult
serum albumin [3].
Transplacental passage of UCB has been assumed to occur
by passive di¡usion [4], but it has not been investigated
whether there exist speci¢c systems for the transport of
UCB across the placenta, akin to those demonstrated in he-
patocytes for UCB [5,6], and in plasma membrane vesicles of
trophoblasts for other organic anions, such as bile acids. For
bile acids, the mechanisms of basolateral uptake are both
passive and carrier-mediated [7]. Export at the apical pole,
however, is ATP-dependent, suggesting the involvement of
an ABC protein [8], most likely the bile salt export pump
(BSEP), which is also present in the liver [9]. Other ABC
proteins, such as MDR1 and CFTR [10,11], as well as multi-
drug resistance-associated proteins MRP1 and MRP5 [12], are
present in both human placenta and hepatocytes.
The mechanism(s) by which UCB is exported across the
apical (maternal-facing) domain of the trophoblast have not
been studied as yet. We, therefore, have investigated the
mechanisms involved in the transfer of UCB across a cell
line (BeWo) derived from human choriocarcinoma [13], which
has been used often as a model to study the mechanisms of
transplacental passage of nutrients and metabolites [14^16].
The results suggest that, in placental cells, UCB is taken up
by carrier-mediated di¡usion and secreted by an active mech-
anism mediated by one or more MRPs.
2. Materials and methods
2.1. Chemicals
[3H]Bilirubin (speci¢c activity 40U103 dpm/Wg) was labeled biosyn-
thetically in bile-¢stula rats by intravenous infusion of 3,5-[3H] N-
aminolevulinic acid and highly puri¢ed as described previously [17].
MK571 was purchased from Alexis (San Diego, CA, USA). All other
reagents, including fatty acid free HSA (lot. no. 93H9345), were of
analytical grade and were obtained from Sigma (Milan, Italy).
2.2. Cell cultures
BeWo cells were cultured under standard conditions in Dulbecco’s
modi¢ed Eagle’s medium with 10% (v/v) fetal calf serum and 1%
antibiotics (10 000 U/ml penicillin and 10 mg/ml streptomycin). The
cells were maintained in 75-cm2 Falcon £asks at pH 7.4 and 37‡C,
under a humidi¢ed atmosphere of 5% CO2. After 3 days in culture,
the cells were harvested by exposure (1^2 min) to 0.25% trypsin and
0.02% EDTA, and transferred onto either 35-mm Petri dishes or onto
Transwell-clear polyester ¢lters (12- or 24-mm diameter) (Costar, New
York, USA). Cells were seeded in dishes at a density of 0.5U106 cells/
dish [18]. The medium was replaced with fresh medium after 24 h and
transport studies were performed the following day. In Transwell
¢lters, cells were seeded at a density of 0.1^0.2U106cells/cm2, and
the medium was replaced every other day. As con¢rmed by achieve-
ment of a maximum transepithelial electrical resistance of 140 6/cm2
(Millicell-ERS epithelial voltohmmeter and electrodes, Millipore
Corp., Bedford, MA, USA) and by phase contrast microscopy [19],
the cells formed polarized, con£uent monolayers in 5 days, and were
used for transport experiments.
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2.3. Measurement of cellular uptake of UCB
All the transport measurements were carried out at room temper-
ature (22^24‡C) and under dim light. Cells grown on dishes were
washed once with 1.5 ml of transport bu¡er (25 mM HEPES/Tris
pH 7.4, 40 mM NaCl, 100 mM sucrose, 5.4 mM KCl, 1.8 mM CaCl2,
0.8 mM MgSO4 and 5 mM glucose). [3H]UCB was dissolved in 30 Wl
DMSO, and diluted 100-fold with transport bu¡er containing 30 WM
HSA. Measurement of uptake was initiated by the addition of 1.0 ml
of this medium containing a free (unbound) UCB concentration [Bf ]
ranging from of 5 to 100 nM [20]. After incubation for 60 s, uptake
was arrested by removing the medium and then immediately washing
the cells three times with 1.5 ml of ice-cold transport bu¡er. The cells
were then dissolved in 1 ml of 2% sodium dodecyl sulfate/0.2 N
NaOH, and 500 Wl of the cell lysate was added to 10 ml of scintillation
liquid (Filtercount, Packard, Groningen, The Netherlands), and ra-
dioactivity measured. Protein content of the cell lysate was measured
with the bicinchonic acid reagent [21].
Cells grown on Transwell polyester ¢lters were handled identically,
except that the uptake medium was added only to the apical (mater-
nal), upper compartment, while the lower, basolateral (fetal) chamber
was loaded with transport bu¡er without UCB or HSA. Procedures
otherwise were the same as for cells grown in dishes. Preliminary
experiments showed that, under these conditions, less than 1% of
the UCB was transferred from the apical to the basal side over 60
min.
2.4. E¥ux experiments
BeWo cells grown on dishes were preincubated for 60 min at 37‡C
with [3H]UCB and 30 WM HSA at [Bf ] ranging from 10 to 40 nM [20].
The medium was then removed and cells were rinsed quickly with 1.5
ml of ice-cold transport bu¡er which contained neither UCB nor
HSA. A volume of 1 ml of transport bu¡er containing 30 WM
HSA, but not UCB, was then added to the cells, and e¥ux of UCB
followed at room temperature for intervals of 0, 5, 10 and 20 min by
radioassay of [3H]UCB retained by the cells as described for the
uptake experiments. The residual UCB at each time interval was ex-
pressed both as pmol UCB/mg protein, and as a percentage of the
initial UCB content following UCB preloading (t0). To assess the
inhibitory e¡ect of other organic anions on UCB e¥ux, BSP, tauro-
cholate and MK571 were added to the transport bu¡er containing 30
WM HSA but not UCB, and retention of UCB by the preloaded cells
measured as above.
Cells grown to con£uence on Transwell were preloaded, by incuba-
tion for 60 min at 37‡C with HSA-bound [3H]UCB placed in the
apical chamber, and then washed as described for the dish-grown
cells. After loading, 1.5 ml of the transport bu¡er without HSA or
UCB was placed in the lower chamber and the apical portion of the
cells exposed for 0^20 min to 1.0 ml of transport bu¡er containing
HSA but not UCB. The retained UCB and protein were analyzed as
for dish-grown cells. The e¡ects on UCB e¥ux of di¡erent organic
anions and MK571 were tested by inclusion in the bu¡ered HSA
solutions placed in the apical chamber.
2.5. Isolation of total RNA and reverse transcriptase polymerase chain
reaction (RT-PCR)
Total cellular RNA was prepared from 3-days-old dish-grown or 5-
days-old ¢lter-grown BeWo cells by a single-step guanidinium isothio-
cyanate^phenol^chloroform extraction procedure [22]. The same pro-
cedure was used to isolate total RNA from normal human placenta
obtained both at term and from the ¢rst trimester (12th week of
gestation).
RT-PCR, to amplify and detect MRP1 and MRP5, was performed
using a Gene Amp PCR system 2400 (Perkin-Elmer, Norwalk, CT,
USA). The sequences of the primers for ampli¢cation of the human
MRP1 gene [23] (accession number L05628) are: sense primer
(CTGTTTTGTTTTCGGGTTCC); antisense primer (GATGGTG-
GACTGGATGAGGT). Sequences for the ampli¢cation of the hu-
man MRP5 gene [12] (accession number U83661) are: sense primer
(CCTGGAGAGGACACACATGA); antisense primer (GGTGTCA-
AACTCCACCACCT). The ampli¢cation of cDNA was run for 30
cycles for MRP1 and 40 cycles for MRP5 at 95‡C for 5 min, 95‡C for
30 s, 57‡C for 30 s, and 72‡C for 30 s. Final elongation was run at
72‡C for 5 min. For each RT-PCR reaction L-actin was ampli¢ed also
(L-actin Control Reagents, PE Biosystems, Foster City, CA, USA).
The PCR products were separated by electrophoresis in 2.5% agarose
gels and visualized by UV light in the presence of ethidium bromide.
2.6. Statistical analysis
For each experiment, UCB transport was measured in duplicate in
at least three separate cell preparations. Results are expressed as
mean þ S.D. of at least three experiments and P values 6 0.05 ob-
tained by two-tailed Student’s t test were considered signi¢cant. Km
and Vmax were determined from a computer-assisted program (Sigma-
Plot, Landel Scienti¢c, San Rafael, CA, USA) according to the Mi-
chaelis^Menten equation.
3. Results
3.1. UCB uptake by BeWo cells
Fig. 1 shows the uptake kinetics of [3H]UCB by non-polar-
ized (Fig. 1A) and polarized (Fig. 1B) cells. In both types of
cells, [3H]UCB uptake exhibited a saturative function when
plotted against the unbound concentration of UCB, [Bf ], in-
dicating a carrier-mediated mechanism. In non-polarized cells
(Fig. 1A), the kinetic constants gave an apparent Km of
37.4 þ 4.9 nM, and a Vmax of 23.9 þ 1.3 pmol UCB/mg protein
per min. When UCB uptake was measured in polarized cells
(Fig. 1B) a comparable apparent Km of 27.2 þ 6.0 nM was
observed, whereas the Vmax was 5.9 þ 0.6 pmol UCB/mg pro-
tein per min, or about one fourth the Vmax in non-polarized
cells (P6 0.001).
As shown in Table 1, UCB uptake in BeWo cells, at
[Bf ] = 15 nM, was not inhibited by the addition of 100^150
WM BSP, 20 WM indomethacin, or 50 WM taurocholate, in-
dicating that the uptake mechanism(s) for UCB were not
Fig. 1. Uptake of [3H]UCB into BeWo cells. Initial [3H]UCB uptake
was measured at room temperature and in dim light by incubating
the cells for 60 s with UCB^HSA solutions yielding 0^90 nM un-
bound (free) UCB [Bf ]. Uptake was expressed as pmol UCB/mg
protein per min. A: UCB uptake by non-polarized cells, grown in a
Petri dish; B: UCB uptake by polarized cells, grown in a Transwell,
from a bu¡ered UCB^HSA solution in the apical-facing, upper
chamber. In both cases, uptake was saturative with similar Km val-
ues but with a Vmax value almost four times greater for non-polar-
ized cells.
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shared by these other organic anions. Conversely, both BSP
and indomethacin enhanced UCB uptake and this e¡ect was
vastly greater when BeWo cells were grown in a polarized
fashion (P6 0.01), suggesting that these two organic anions
may interfere with the cellular e¥ux of UCB. Such enhance-
ment was not seen when taurocholate was added.
3.2. UCB e¥ux from preloaded BeWo cells
UCB e¥ux from preloaded BeWo cells was measured in the
absence and presence of BSP and taurocholate. Fig. 2A shows
that, after incubation for 60 min at [Bf ] of 15 nM, non-polar-
ized cells grown in dishes took up over twice as much UCB
compared to polarized cells grown in Transwells (109 þ 12 vs.
46 þ 7 pmol UCB/mg protein, P6 0.001). Fig. 2B shows that,
when preloaded non-polarized cells were exposed to a medium
without UCB, but containing 30 WM HSA to trap UCB (con-
trol), the intracellular UCB content decreased progressively to
25 þ 5% at 20 min (P6 0.001 vs. time 0). Addition of 150 WM
BSP decreased UCB e¥ux signi¢cantly, with virtually all
UCB retained at 10 min (P6 0.01 vs. control) and 41 þ 5%
retained at 20 min (P6 0.01 vs. control). With preloaded po-
larized cells grown on Transwells (Fig. 2C), addition of 150
WM BSP likewise inhibited UCB e¥ux markedly; virtually all
the initial UCB was retained at 10 min and 62 þ 6% after 20
min (P6 0.002 vs. non-polarized cells, P6 0.01 vs. polarized
controls). In both polarized and non-polarized cells, 50 WM
taurocholate and 20 WM indomethacin did not a¡ect cellular
release of UCB.
To test the possible involvement of MRP family member(s)
in UCB e¥ux, BeWo cells preloaded with UCB were exposed
to 100 WM of MK571, a speci¢c inhibitor of the function of
MRP proteins [23,24]. As shown in Fig. 3, UCB e¥ux from
polarized BeWo cells was nearly abolished by MK571 at 10
min and, after 20 min, 81 þ 7% of the initial UCB content was
still retained (time 0). A signi¢cant but lower inhibitory e¡ect
of MK571 was observed in non-polarized BeWo cells
(P6 0.01 vs. control, and P6 0.05 vs. polarized cells).
3.3. MRP expression in BeWo cells and human placenta by
RT-PCR analysis
The expression of the genes encoding MRP proteins was
studied by RT-PCR analysis of total RNA extracted from
BeWo cells grown for 3 days in dishes or for 5 days on Trans-
well, and compared to that observed in total human placenta.
A band of the expected size (287 bp) (Fig. 4, upper panel) was
obtained from RNA prepared from placenta harvested during
the ¢rst (lane 3) and the third (lane 4) trimester of pregnancy.
A band of the same size was also observed in RNA extracted
Table 1
E¡ect of other organic anions on UCB uptake in BeWo cells
Non-polarized BeWo cellsa Polarized BeWo cellsb
UCB transport
(pmol/mg protein per min)
Change vs. control (%) UCB transport
(pmol/mg protein per min)
Change vs. control (%)
Control (UCB+HSA) 8.3 þ 0.8 2.1 þ 0.4
+BSP 100 WM 10.5 þ 0.7 +26 þ 24 6.3 þ 0.8* +200 þ 38*
+BSP 150 WM 11.4 þ 0.8 +38 þ 34 10.1 þ 1.1* +380 þ 52*
+Indomethacin 20 WM 9.2 þ 0.6 +7 þ 0.5 4.5 þ 0.6* +114 þ 28*
+Taurocholate 50 WM 8.1 þ 0.9 33 þ 1 2.3 þ 0.4 +10 þ 9
Initial uptake was measured for 60 s at 22^24‡C at concentrations of 5 WM [3H]UCB and 30 WM HSA ([Bf ] = 15 nM), in the presence or ab-
sence of possible competitors. 4P6 0.02 and *P6 0.001 vs. control.
aGrown in Petri dishes.
bGrown on Transwell ¢lters.
Fig. 2. Cellular uptake and e¥ux of [3H]UCB. Cells were preloaded
by exposure to 5 WM [3H]UCB and 30 WM HSA ([Bf ] = 15 nM) for
60 min at 37‡C in the dark. Cells were then washed and exposed to
a medium containing 30 WM HSA without UCB, and residual cellu-
lar content of [3H]UCB determined by radioassay at di¡erent inter-
vals. A: Cellular content after 60 min of preloading from a UCB^
HSA solution in Transwell (white bar) and dishes (black bar). B:
UCB content of non-polarized, dish-grown cells at di¡erent time in-
tervals. UCB content decreased over time (white bars). When 150
WM BSP was added (black bars) UCB e¥ux was signi¢cantly im-
paired both after 10 and at 20 min. The addition of 50 WM tauro-
cholate (gray bars) did not a¡ect cellular release of UCB. C: UCB
content of polarized, Transwell-grown cells after di¡erent time inter-
vals. As with non-polarized cells, BSP (black bars) but not tauro-
cholate (gray bars) signi¢cantly inhibited UCB cellular extrusion.
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from BeWo cells, but the intensity was greater in RNA de-
rived from polarized cells (lane 2) than from non-polarized
cells (lane 1), suggesting that polarization is associated with
an increased expression of MRP1. As shown in the middle
panel of Fig. 4, expression of MRP5 was observed also, both
in human placenta at the two di¡erent gestational ages as well
as in polarized and non-polarized BeWo cells. In the case of
MRP5, an evident ampli¢cation was obtained only after 40
cycles, suggesting a lower level of expression of this ABC gene
as compared to MRP1 both in human placenta and in BeWo
cell line.
4. Discussion
These data indicate that BeWo cells take up UCB by a
saturative mechanism not shared by BSP, taurocholate or in-
domethacin and that, after entry into cell, UCB is secreted via
a process which is inhibited by BSP and by the speci¢c inhib-
itor of MRP proteins, MK571. These results, showing that
BeWo choriocarcinoma cells are able to transport UCB at
unbound concentrations below the maximum aqueous solubil-
ity of 70 nM [25], suggest that the trophoblasts of the human
placenta may utilize carrier-mediated processes to e⁄ciently
transfer UCB from the fetus to the mother [26]. This is in
contrast to the long-held belief that this process is simply
due to passive di¡usion [4].
The uptake process in BeWo cells was saturative. The sat-
urative kinetics and the apparent a⁄nity constant (Km) value
we observed in BeWo cells are similar to those we found
previously in rat liver basolateral plasma membrane vesicles
[20] and freshly isolated rat hepatocytes [17], indicating that
this phenomenon may act at physiological conditions. While
the apparent Km value was comparable in polarized and non-
polarized BeWo cells, the Vmax value was almost three times
greater in the non-polarized cells. This is likely due to (a) a
di¡erent expression of carrier molecules in polarized and non-
polarized cells, and/or (b) a greater countervailing cellular
e¥ux of UCB in polarized cells.
BSP, an organic anion which reportedly shares some of the
uptake mechanisms of UCB in the liver [20,27], did not in-
hibit, but actually enhanced UCB uptake in non-polarized
BeWo cells, especially when added to the apical compartment
of polarized cells on the Transwell (Table 1). This is evidence
that mechanisms for UCB uptake across the membrane of
BeWo cells and, by inference, normal placental trophoblasts
di¡er from those in hepatocytes. It suggests further that UCB
uptake does not involve the OATP family, which is expressed
in the human placenta [28], but does not appear to be in-
volved in the transport of UCB [29] while it is actively in-
volved in BSP uptake [30]. The lack of inhibition of UCB
uptake by taurocholate further supports this conclusion, since
taurocholate is also transported by OATP proteins.
The data shown in Fig. 2, together with the stimulatory
e¡ect on UCB uptake elicited by BSP and indomethacin,
Fig. 3. Inhibition of cellular e¥ux of [3H]UCB by MK571. Cells
were preloaded with [3H]UCB as in Fig. 2, and UCB e¥ux followed
at various time intervals in the absence or presence of 100 WM
MK571. Data are expressed as % of the initial content (time 0)
which was retained. Inhibition of UCB e¥ux by MK571 was great-
er in polarized cells (black bars) as compared to that observed in
non-polarized cells (gray bars). The percentage of [3H]UCB released
over the time by non-polarized (stripped bars) and polarized (white
bars) cells was similar, in spite of the greater initial content of
[3H]UCB after preloading in non-polarized cells.
Fig. 4. MRP1 and MRP5 expression in human placental tissue and
BeWo cells assessed by RT-PCR. RNA was extracted from human
placenta at the ¢rst and third trimester and from BeWo cells grown
on dishes or Transwells. PCR products stained with ethidium bro-
mide were visualized under UV light. MRP1 and MRP5 were de-
tected in all samples. The ampli¢cation of MRP1 after 30 cycles re-
sulted in a product of 287 bp, which was much more highly
expressed in polarized than in non-polarized BeWo cells. MRP1 ex-
pression was rather comparable in human placenta at the two di¡er-
ent gestational ages. Expression of MRP5, as detected after 40
cycles of ampli¢cation (325 bp), was not signi¢cantly di¡erent be-
tween polarized vs. non-polarized cells, or in the placenta from the
third vs. the ¢rst trimester. In both tissues, MRP1 was more highly
expressed than MRP5.
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but not taurocholate (Table 1), suggest that, in BeWo cells,
particularly when polarized, UCB may be exported by a
transport mechanism which is also shared by BSP and indo-
methacin; their inhibition of e¥ux of the pigment from the
cell increases the ‘net’ uptake of UCB. This concept is sup-
ported by the ¢nding (Fig. 2) that addition of BSP to the
external medium strikingly decreased e¥ux of UCB from pre-
loaded BeWo cells in a time-dependent fashion, both in non-
polarized and polarized cells. The partial escape from this
inhibition at 20 min as compared with 10 min is likely due
to export of BSP from the cell after initial loading, and sug-
gests that BSP cis-inhibited the extrusion of UCB, particularly
at the apical level, as indicated by the greater inhibition in
polarized cells. As with uptake, taurocholate did not in£uence
cellular e¥ux of UCB, indicating that the export protein for
UCB at the apical pole of the BeWo cells apparently does not
transport taurocholate, thus excluding the involvement of the
BSEP [31].
The nearly complete abolition of the apical UCB e¥ux
from BeWo cells by MK571, a speci¢c inhibitor of MRP
proteins [24], and considerable inhibition by BSP and indo-
methacin, known to be substrates for MRP proteins at con-
centrations similar to those used in the present study [32],
suggest the involvement of an MRP protein in the export of
UCB from these cells. This was also shown by our recent data
indicating that UCB is a substrate for both YCF1 and
YLL015 gene products in yeast [33]. Of the six MRP genes
in Saccharomyces cerevisiae, YCF1 and YLL015 show the
greatest homology for human MRP1 and MRP2 [34,35].
The involvement of MRP2 in ATP-dependent export of
UCB from mammalian cells has previously been excluded,
since liver plasma membrane vesicles derived from TR3
rats, genetically de¢cient in mrp2, retain unimpaired ATP-de-
pendent transport of UCB [36]. As in human placenta, PCR
analysis revealed the presence of both MRP1 and MRP5 in
BeWo cells, whether non-polarized or polarized (Fig. 4). The
association of higher UCB e¥ux in polarized BeWo cells with
a higher expression of MRP1, without a parallel increase of
MRP5 expression, supports a major role of MRP1 in UCB
transport. The additional involvement of other MRPs in the
whole placenta cannot be excluded, however, since the pups of
mrp1-knockout mice do not evidence excessive hyperbilirubi-
nemia or UCB toxicity at birth [37]. The low and unchanged
level of MRP5 mRNA before and after polarization, together
with the recent report that MRP5 is involved in the transport
of nucleotide analogues [38], renders it unlikely that this car-
rier plays an active role in UCB transport
Collectively, our data point to the existence of speci¢c
transporters of UCB at both the basal (fetal-facing) and apical
(maternal-facing) membranes of the trophoblast, that mediate
the passage of UCB from fetal to maternal blood. The
marked inhibition by MK571 of UCB export from polarized
BeWo cells strongly suggests that the extrusion of UCB is
accounted for by an MRP protein. Although the molecular
mechanisms of placental uptake of UCB from the fetus re-
main unde¢ned, our studies suggest that MRP1 may mediate
UCB transfer from the placental trophoblasts to the maternal
circulation, and thus protect the fetus from UCB toxicity.
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